Improved balance between TIMP-3 and MMP-9 after regional myocardial ischemia-reperfusion during AT1 receptor blockade

Journal of Cardiac Failure

Volumn 10, Issue 5, 2004, Pages 442-449

  Sawicki, Grzegorz ^a,b   Menon, Vijayan ^a,b   Jugdutt, Bodh I ^a,b,c  

^a University of Alberta ^*

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiotensin II; Cardioprotection; Function; Matrix metalloproteinases; Receptor

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TISSUE INHIBITOR OF METALLOPROTEINASE 4; VALSARTAN; ANGIOTENSIN RECEPTOR ANTAGONIST; DRUG DERIVATIVE; GELATINASE A; TETRAZOLE DERIVATIVE; VALINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOG; ELECTROPHORESIS; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEMODYNAMICS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REPERFUSION; STATISTICAL ANALYSIS; WESTERN BLOTTING; ANIMAL; BLOOD PRESSURE; DENSITOMETRY; DISEASE MODEL; DRUG EFFECT; ELECTROCARDIOGRAPHY; HEART INFARCTION; HEART MUSCLE REPERFUSION; HEART RATE; METABOLISM; PATHOPHYSIOLOGY; RANDOMIZATION; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BLOOD PRESSURE; BLOTTING, WESTERN; DENSITOMETRY; DISEASE MODELS, ANIMAL; DOGS; ELECTROCARDIOGRAPHY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; HEART RATE; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RANDOM ALLOCATION; TETRAZOLES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TREATMENT OUTCOME; VALINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 21644433632     PISSN: 10719164     EISSN: 15328414     Source Type: Journal    
DOI: 10.1016/j.cardfail.2004.01.012     Document Type: Article

References (29)

1. 1 receptor blockade in reperfused myocardial infarction. In: N. Dhalla, editor. Signal transduction and cardiac hypertrophy. Boston: Kluwer Academic Publishers; 2002. p. 221-36.
2. ε proteins. J Renin-Angiotensin Aldosterone Syst 2000;1:184-95.
3. Yoshiyama M, Kim S, Yamagishi H, Omura T, Tani T, Yanagi S, et al. Cardioprotective effect of the angiotensin II type 1 receptor antagonist TCV-116 on ischemia-reperfusion injury. Am Heart J 1994;128:1-6.
4. Youhua Z, Shouchun X. Increased vulnerability of hypertrophied myocardium to ischemia and reperfusion injury. Relation to cardiac renin-angiotensin system. Chin Med J 1995;108:28-32.
5. Tyagi SC, Bheemanathini VS, Mandi D, Reddy HK, Voelker DJ. Role of extracellular matrix metalloproteinases in cardiac remodeling. Heart Fail Rev 1996;1:73-80.
6. Mann DL. Inflammatory mediators and the failing heart. Past, present, and the foreseeable future. Circ Res 2002;91:988-98.
7. Jugdutt BI. Ventricular remodeling postinfarction and the extracellular collagen matrix. When is enough enough? Circulation 2003;108:1395-403.
8. Cleutjens JP, Kandala JC, Guarda E, Guntaka RV, Weber KT. Regulation of collagen degradation in the rat myocardium after infarction. J Mol Cell Cardiol 1995;27:1281-92.
9. Tyagi SC, Kumar SG, Banks J, Fortson W. Co-expression of tissue inhibitor and matrix metalloproteinase in myocardium. J Mol Cell Cardiol 1995;27:2177-89.
10. Li YY, Feldman AM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34.
11. Mayers I, Hurst T, Puttagunta L, Radomski A, Mycyk T, Sawicki G, et al. Cardiac surgery increases the activity of matrix metalloproteinases and nitric oxide synthase in human hearts. J Thorac Cardiovasc Surg 2001;122:746-52.
12. Danielsen CC, Wiggers H, Andersen HR. Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 1998;30:1431-42.
13. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-42.
14. Wang W, Sawicki G, Schulz R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc Res 2002;53:165-74.
15. Cheung PY, Sawicki G, Wozniak M, Wang W, Radomski MW, Schulz R. Matrix metalloproteinase-2 contributes to ischemia-reperfusion injury in the heart. Circulation 2000;101:1833-9.
16. Wang W, Schulze CJ, Suarez-Pinzon WL, Dyck JR, Sawicki G, Schulz R. Intracellular action of matrix metalloproteinase-2 accounts for acute myocardial ischemia and reperfusion injury. Circulation 2002;106:1543-9.
17. Fedak PW, Altamentova SM, Weisel RD, Nili N, Ohno N, Verma S, et al. Matrix remodeling in experimental and human heart failure: a possible regulatory role for TIMP-3. Am J Physiol 2003;284:H626-34.
18. Schulze C, Wang W, Suarez-Pinson WL, Sawicki J, Sawicki G, Schulz R. Imbalance between tissue inhibitor of metalloproteinase-4 and matrix metalloproteinases during acute myocardial ischemia-reperfusion injury. Circulation 2003;107:2487-92.
19. Matsumura K, Jeremy RW, Schaper J, Becker LC. Progression of myocardial necrosis during reperfusion of ischemic myocardium. Circulation 1998;97:795-804.
20. 1 receptor blockade after reperfused myocardial infarction. J Renin-Angiotensin Aldosterone Syst 2001;2:134-40.
21. Zhao MJ, Zhang H, Robinson TF, Factor SM, Sonnenblick EH, Eng C. Profound structural alterations of the extracellular collagen matrix in postischemic dysfunctional ("stunned") but viable myocardium. J Am Coll Cardiol 1987;10:1322-34.
22. Greene J, Wang M, Liu YE, Raymond LA, Rosen C, Shi YE. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4. J Biol Chem 1996;271:30375-80.
23. Gilbert SJ, Wotton PR, Tarlton JF, Duance VC, Bailey AJ. Increased expression of promatrix metalloproteinase-9 and neutrophil elastase in canine dilated cardiomyopathy. Cardiovasc Res 1997;34:377-83.
24. Lu L, Gunja-Smith Z, Woessner JF, Ursell PC, Nissen T, Galardy RE, et al. Matrix metalloproteinases and collagen ultrastructure in moderate myocardial ischemia and reperfusion in vivo. Am J Physiol 2000; 279:H601-9.
25. Li YY, Feng Y, McTiernan CF, Pei W, Moravec CS, Wang P, et al. Downregulation of matrix metalloproteinases and reduction in collagen damage in the failing human heart after support with left ventricular assist devices. Circulation 2001;104:1147-52.
26. Rouet-Benzineb P, Buhler JM, Dreyfus P, Delcourt A, Doren R, Perennec J, et al. Altered balance between matrix gelatinases (MMP-2 and MMP-9) and their tissue inhibitors in human dilated cardiomyopathy: potential role of MMP-9 in myosin-heavy chain degradation. Eur J Heart Fail 1999;1:337-52.
27. Reinhardt D, Sigusch HH, Hensse J, Tyagi SC, Körfer R, Figulla HR. Cardiac remodeling in end stage heart failure: upregulation of matrix metalloproteinase (MMP) irrespective of the underlying disease, and evidence for a direct inhibitory effect of ACE inhibition on MMP. Heart 2002;88:525-30.
28. Wilson EM, Moainie SL, Baskin JM, Lowry AS, Deschamps AM, Mukherjee R, et al. Region- and type-specific induction of matrix metalloproteinases in post-myocardial infarction remodeling. Circulation 2003;107:2857-63.
29. Jugdutt BI, Tang SB, Khan MI, Basualdo CA. Functional impact of remodeling during healing after non-Q wave versus Q wave anterior myocardial infarction in the dog. J Am Coll Cardiol 1992;20:722-31.